Immunic (NASDAQ:IMUX) released its quarterly earnings data on Thursday. The company reported ($0.82) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.67) by ($0.15), Fidelity Earnings reports.
NASDAQ IMUX traded down $0.35 on Friday, reaching $8.01. 18,900 shares of the company were exchanged, compared to its average volume of 126,712. The firm has a fifty day simple moving average of $9.77. The company has a market cap of $86.77 million, a PE ratio of -0.23 and a beta of 3.51. Immunic has a fifty-two week low of $6.00 and a fifty-two week high of $46.80.
A number of equities analysts have weighed in on IMUX shares. ValuEngine raised Immunic from a “hold” rating to a “buy” rating in a research note on Saturday, October 5th. Zacks Investment Research raised Immunic from a “sell” rating to a “hold” rating in a research note on Wednesday, October 30th. Finally, Chardan Capital reissued a “buy” rating on shares of Immunic in a research note on Thursday, September 19th.
Immunic, Inc, a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies for treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. Its lead development program is IMU-838, a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH, which is in phase II clinical development for treatment of ulcerative colitis and relapsing-remitting multiple sclerosis.
Recommended Story: Market Capitalization and Individual Investors
Receive News & Ratings for Immunic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunic and related companies with MarketBeat.com's FREE daily email newsletter.